Literature DB >> 7126413

An oral preparation to release drugs in the human colon.

M J Dew, P J Hughes, M G Lee, B K Evans, J Rhodes.   

Abstract

1 A colonic delivery system is described to deliver orally ingested drugs to the colon and release them at that site by coating with an acrylic based resin (Eudragit S). The technique is validated using X-ray evidence and serum levels of a convenient marker, sulphapyridine. 2 This colonic delivery system is particularly suitable for drugs such as 5-amino salicylic acid or steroids in the management of patients with colitis.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7126413      PMCID： PMC1427636          DOI： 10.1111/j.1365-2125.1982.tb01999.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  10 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Retrograde colonic spread of enemata in ulcerative colitis.

Authors:  S G MATTS; K H GASKELL
Journal:  Br Med J       Date:  1961-09-02

3.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

4.  Male infertility due to sulphasalazine.

Authors:  A J Levi; A M Fisher; L Hughes; W F Hendry
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

5.  Sulphasalazine and male infertility: reversibility and possible mechanism.

Authors:  S Toovey; E Hudson; W F Hendry; A J Levi
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

6.  Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device.

Authors:  R L Bown; J A Gibson; G E Sladen; B Hicks; A M Dawson
Journal:  Gut       Date:  1974-12       Impact factor: 23.059

7.  A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Authors:  A S Dissanayake; S C Truelove
Journal:  Gut       Date:  1973-12       Impact factor: 23.059

8.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

9.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321
  10 in total
  41 in total

1.  Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system.

Authors:  I Krögel; R Bodmeier
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

Authors:  R A van Hogezand; H M Kennis; A van Schaik; J P Koopman; P A van Hees; J H van Tongeren
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

4.  Acute pancreatitis during oral 5-aminosalicylic acid therapy.

Authors:  M T Fiorentini; M Fracchia; G Galatola; A Barlotta; M de la Pierre
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

5.  Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems.

Authors:  Valentine C Ibekwe; Hala M Fadda; Emma L McConnell; Mandeep K Khela; David F Evans; Abdul W Basit
Journal:  Pharm Res       Date:  2008-05-09       Impact factor: 4.200

Review 6.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

Review 7.  Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis.

Authors:  E Adachi; K Okazaki; Y Matsushima; H Seno; K Uchida; H Nakase; C Kawanami; T Nakamura; T Chiba
Journal:  Int J Pancreatol       Date:  1999-06

8.  The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.

Authors:  I P Donald; S P Wilkinson
Journal:  Postgrad Med J       Date:  1985-12       Impact factor: 2.401

9.  Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.

Authors:  F N Hussain; R A Ajjan; M Moustafa; N W Weir; S A Riley
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

Authors:  I M Nakshabendi; A Duncan; R I Russell
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.